Search the Newsreel

Denali sets Aug. 6 webcast on medicines crossing the blood-brain barrier

Denali Therapeutics (Nasdaq: DNLI) will report its second quarter 2026 financial results and business highlights on Thursday, August 6, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. The company is …

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

Denali Therapeutics Inc. announced it will report its Q2 2026 financial results and business highlights on Thursday, August 6, 2026. The report will be followed by a conference call and webcast hosted by Denali's management to discuss the results and provide a general business …

Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Denali Therapeutics Inc (DNLI), listing its major shareholders and their respective proportions, including Baillie Gifford & Co., BlackRock Institutional Trust Company, N.A., and T. Rowe Price Investment Management, Inc. It also breaks down shareholder types by proportion, …

Denali Therapeutics Inc. Revenue Breakdown – NASDAQ:DNLI

This article provides a brief overview of Denali Therapeutics Inc. (NASDAQ: DNLI) financials, specifically focusing on its revenue breakdown. It highlights that detailed revenue segmentation by source and country is available, powered by data from ICE Data Services and FactSet. The content is primarily …

Denali Therapeutics Inc (DNLI) Valuation: PE, PB & Fair Value Analysis

Denali Therapeutics Inc (DNLI) currently holds a valuation score of 7.56, placing it 225th out of 386 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -8.02, which represents a significant fluctuation compared to its recent high and low. Other key …

DNLI|Denali Therapeutics Inc|Price:23.110|Chg%:-0.310

Denali Therapeutics Inc (DNLI) is a biopharmaceutical company focused on neurodegenerative and lysosomal storage diseases, with a current stock price of $23.110. The company's fundamentals are weak, but its growth potential is high, and it is considered fairly valued by analysts. Despite recent weak …

Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36

Morgan Stanley has reiterated its Buy rating for Denali Therapeutics (DNLI.US) and increased its target price to $36. This updated target suggests a positive outlook for the company's stock from the investment bank.

DNLI Maintained by Morgan Stanley -- Price Target Raised to $36

Morgan Stanley analyst Matthew Harrison maintained an "Overweight" rating on Denali Therapeutics (DNLI) and increased the price target from $35.00 to $36.00. While the company demonstrates financial strength and momentum, its low profitability and valuation scores suggest caution for investors. Denali Therapeutics, a biotechnology …

Denali Therapeutics (DNLI) Stock May Trade At A 12% Premium Following AAIC 2026 Plenary News

Denali Therapeutics (DNLI) has seen a 63.4% return over the past year, but valuation models suggest its stock is currently trading at a premium. Both a Discounted Cash Flow (DCF) analysis and Price-to-Book (P/B) ratio indicate the company is overvalued, with the DCF model …

Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval?

Denali Therapeutics (DNLI) has seen a 71.8% return over the past year, but valuation checks suggest it's currently overvalued. Both the Discounted Cash Flow (DCF) model and Price-to-Book (P/B) ratio indicate the stock is trading at a premium, even though the recent FDA approval …

Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline

Denali Therapeutics (DNLI) stock remains steady, driven by advancements in its ALS program (DNL343) and a strong cash position of $1.30 billion as of March 31, 2024. The company reported a 50% year-over-year revenue increase in Q1 2024, reaching $120 million, largely due to …

Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey?

Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return

Denali Therapeutics (DNLI) is poised to present at an Alzheimer's conference, drawing attention to its neurodegenerative disease research pipeline. While the stock has seen a 66.36% increase over the past year, it remains about 47% below the average analyst price target, raising valuation questions. …

Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35

Deutsche Bank has reiterated its Buy rating on Denali Therapeutics (DNLI.US) and increased its target price for the stock to $35. This revised target price suggests a potential upside for investors, reflecting Deutsche Bank's positive outlook on the company's future performance.

Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC)

Two healthcare companies, Denali Therapeutics (DNLI) and Celcuity (CELC), have received bullish ratings from analysts. Denali Therapeutics secured a Strong Buy consensus with a significant upside, while Celcuity also garnered a Strong Buy with a high price target. These recommendations highlight strong analyst confidence …